Bellicum Pharmaceuticals Stock Short Ratio
Bellicum Pharmaceuticals fundamentals help investors to digest information that contributes to Bellicum Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Bellicum Pink Sheet. The fundamental analysis module provides a way to measure Bellicum Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bellicum Pharmaceuticals pink sheet.
Bellicum |
Bellicum Pharmaceuticals Company Short Ratio Analysis
Bellicum Pharmaceuticals' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Bellicum Pharmaceuticals Short Ratio | 0.17 X |
Most of Bellicum Pharmaceuticals' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bellicum Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
CompetitionBased on the latest financial disclosure, Bellicum Pharmaceuticals has a Short Ratio of 0.17 times. This is 95.64% lower than that of the Biotechnology sector and 97.71% lower than that of the Health Care industry. The short ratio for all United States stocks is 95.75% higher than that of the company.
Bellicum Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bellicum Pharmaceuticals' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bellicum Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Bellicum Pharmaceuticals by comparing valuation metrics of similar companies.Bellicum Pharmaceuticals is currently under evaluation in short ratio category among its peers.
Bellicum Fundamentals
Return On Equity | -1.06 | |||
Return On Asset | -0.61 | |||
Operating Margin | (19.69) % | |||
Current Valuation | (38.62 M) | |||
Shares Outstanding | 9.5 M | |||
Shares Owned By Insiders | 4.19 % | |||
Shares Owned By Institutions | 29.30 % | |||
Number Of Shares Shorted | 1.44 M | |||
Price To Earning | 8.50 X | |||
Price To Book | 1.00 X | |||
Price To Sales | 5.46 X | |||
Revenue | 1.5 M | |||
Gross Profit | (17.38 M) | |||
EBITDA | (28.93 M) | |||
Net Income | (24.97 M) | |||
Cash And Equivalents | 33.17 M | |||
Cash Per Share | 3.85 X | |||
Total Debt | 58 K | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 8.07 X | |||
Book Value Per Share | (1.11) X | |||
Cash Flow From Operations | (25.78 M) | |||
Short Ratio | 0.17 X | |||
Earnings Per Share | (1.57) X | |||
Target Price | 5.0 | |||
Number Of Employees | 13 | |||
Beta | 1.57 | |||
Market Capitalization | 3.52 M | |||
Total Asset | 23.82 M | |||
Retained Earnings | (575.42 M) | |||
Working Capital | 20.03 M | |||
Current Asset | 96.89 M | |||
Current Liabilities | 7.45 M | |||
Z Score | -0.31 | |||
Net Asset | 23.82 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Bellicum Pink Sheet
If you are still planning to invest in Bellicum Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellicum Pharmaceuticals' history and understand the potential risks before investing.
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |